We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $318M
This Fund
S&P 500
This Quarter Est. Return
+43.96%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$148M
AUM Growth
–
Cap. Flow
+$138M
Cap. Flow %
93.63%
Top 10 Hldgs %
68.44%
Holding
85
New
85
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$62.7M
2
SLNO
Soleno Therapeutics
SLNO
+$7.13M
3
COGT icon
Cogent Biosciences
COGT
+$6.02M
4
RVMD icon
Revolution Medicines
RVMD
+$4.31M
5
TERN
Terns Pharmaceuticals
TERN
+$3.01M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
51
Prothena Corp
PRTA
$450M
$414K 0.28%
+43,300
New +$441K
NRIX icon
52
Nurix Therapeutics
NRIX
$2.65B
$379K 0.26%
+20,000
New +$287K
SVRA icon
53
Savara
SVRA
$1.19B
$378K 0.26%
+62,762
New +$307K
TARS icon
54
Tarsus Pharmaceuticals
TARS
$2.84B
$368K 0.25%
+4,500
New +$336K
PLRX icon
55
Pliant Therapeutics
PLRX
$65M
$337K 0.23%
+276,500
New +$415K
ACRS icon
56
Aclaris Therapeutics
ACRS
$869M
$323K 0.22%
+107,419
New +$271K
SEPN
57
Septerna Inc
SEPN
$1.75B
$319K 0.22%
+11,445
New +$273K
CLYM
58
Climb Bio
CLYM
$804M
$306K 0.21%
+76,400
New +$183K
CMPS
59
Compass Pathways
CMPS
$1.83B
$276K 0.19%
+40,000
New +$244K
BEAM icon
60
Beam Therapeutics
BEAM
$2.84B
$264K 0.18%
+9,537
New +$243K
ENTX icon
61
Entera Bio
ENTX
$141M
$263K 0.18%
+135,318
New +$317K
VKTX icon
62
Viking Therapeutics
VKTX
$4B
$211K 0.14%
+6,000
New +$213K
QURE icon
63
uniQure
QURE
$3.22B
$209K 0.14%
+8,742
New +$337K
CTMX icon
64
CytomX Therapeutics
CTMX
$754M
$208K 0.14%
+48,898
New +$186K
OCUL icon
65
Ocular Therapeutix
OCUL
$2.02B
$208K 0.14%
+17,100
New +$208K
ORKA
66
Oruka Therapeutics
ORKA
$5.96B
$159K 0.11%
+5,240
New +$146K
NAMS icon
67
NewAmsterdam Pharma
NAMS
$3.34B
$140K 0.1%
+4,000
New +$146K
AMLX icon
68
Amylyx Pharmaceuticals
AMLX
$2.54B
$140K 0.09%
+11,571
New +$157K
APGE icon
69
Apogee Therapeutics
APGE
$10.2B
$136K 0.09%
+1,800
New +$113K
ALXO icon
70
ALX Oncology
ALXO
$290M
$133K 0.09%
+117,817
New +$178K
VSTM icon
71
Verastem
VSTM
$610M
$117K 0.08%
+15,140
New +$135K
RGC icon
72
Regencell Bioscience
RGC
$2.68B
$92.4K 0.06%
+4,400
New +$71.5K
TRVI icon
73
Trevi Therapeutics
TRVI
$2.64B
$89K 0.06%
+7,110
New +$82.2K
IMUX icon
74
Immunic
IMUX
$195M
$82.8K 0.06%
+15,522
New +$114K
PMVP icon
75
PMV Pharmaceuticals
PMVP
$63.5M
$79.4K 0.05%
+63,498
New +$85.1K
1 2
3
4

Similar funds

CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
SA
SAM Advisors Oakhurst, California $319M AUM 17.08% 1-Year Est. Return
TM
TigerOak Management Albuquerque, New Mexico $317M AUM 25.39% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $317M AUM 17.24% 1-Year Est. Return
FPWM
FSB Premier Wealth Management Waterloo, Iowa $319M AUM 15.64% 1-Year Est. Return
KI
Keewaydin Investments Southampton, New York $317M AUM
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
SGF
Stephens Greth Foundation Dallas, Texas $320M AUM

Seven Fleet Capital Management's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for Seven Fleet Capital Management, which disclosed 85 positions worth $148M. Its ten largest holdings account for 68% of the portfolio.

Its largest position is CG Oncology: 1,515,151 shares worth $62.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Seven Fleet Capital Management's largest Q4 2025 buy was CG Oncology: 1,515,151 shares worth $62.9M.
  • Seven Fleet Capital Management's ten largest holdings make up 68% of its $148M portfolio in Q4 2025.
  • Seven Fleet Capital Management disclosed 85 positions in Q4 2025, its first 13F filing on record.

Based on Seven Fleet Capital Management's 13F filing for Q4 2025, filed 26 Feb 2026.